School of Biomedical Sciences

Skip Navigation |

  1. Background
  2. Contact
  3. Publications

O’Harte, Finbarr Professor

Professor of Endocrinology & Metabolism

Academic and Professional Qualifications
- 2003: Member of Institute of Learning and Teaching (ILT)
- 1989: PhD Veterinary Science, Queen’s University of Belfast
- 1986: BSc Hons Biochemistry, Queen’s University of Belfast

Career History
- 2005 - present:Professor of Endocrinology & Metabolism, University of Ulster
- 1995 - 2000: Lecturer in Nutrition & Metabolism, University of Ulster
- 1993 - 1995: Research Officer, University of Ulster
- 1992 - 1993: Postdoctoral Research Fellow, University College, Cork
- 1989 - 1991: Postdoctoral Research Fellow, Creighton University, Omaha, NE, USA

Teaching & Learning Activities

Biochemistry, Endocrinology, Analytical Chemistry

Brief profile

- BSc Hons and PhD from Queen’s University Belfast. Research Fellow at Creighton University, Omaha, USA (1989-91), University College Cork (1992-93) and University of Ulster (1993-95) before taking up an academic appointment at the University of Ulster in 1995. Promoted to Reader in 2000 and Professor of Endocrinology and Metabolism in 2005. Patent holder and academic co-founder of Diabetica Limted, a UU start-up company focused on innovative diabetes therapeutics. Over 180 peer-reviewed publications with many presentations at national and international conferences and was recipient of the Nordisk Medal of the Irish Endocrine Society (2005). Research interests

- structurally modified peptides in therapy and drug development
- role of regulatory peptides in control of feeding and obesity
- incretin hormone analogues in diabetes therapy
- structure-function activity of peptides
- hormone receptor modelling and NMR
- glucagon receptor antagonists in diabetes therapy

Teaching interests

- Diabetes Metabolism and Therapeutics, Hormone Action and Endocrinology.

O’Harte, Finbarr Professor

space

Professor Finbarr O'Harte
Professor of Endocrinology & Metabolism
Biomedical Sciences Research Institute

space

Room Y127
School of Biomedical Sciences
University of Ulster
Coleraine campus
Cromore Road
Coleraine
Co. Londonderry
BT52 1SA

phone: +44 28 70124853
Email: fpm.oharte@ulster.ac.uk

O’Harte, Finbarr Professor - Publications

Number of items: 183.

Franklin, ZJ, O'Harte, Finbarr and Irwin, Nigel (2014) Effects of short-term chemical ablation of glucagon signaling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice. Biological Chemistry, 395 (4). pp. 433-442.

O'Harte, Finbarr, Franklin, ZJ, Rafferty, EP and Irwin, Nigel (2013) Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists. Molecular and Cellular Endocrinology, 381 (1-2). pp. 26-34.

Irwin, Nigel, Frizelle, P, O'Harte, Finbarr and Flatt, Peter (2013) (pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes. Biochimica et Biophysica Acta - General Subjects, 1830 (8). pp. 4009-4016.

Irwin, Nigel, Franlin, ZJ and O'Harte, Finbarr (2013) desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.. European Journal of Pharmacology, 709 (1-3). pp. 43-51.

Irwin, Nigel, Frizzelle, P, O'Harte, Finbarr and Flatt, Peter (2013) Metabolic effects of activation of CCK receptor signaling pathways by twice daily administration of the enzyme resistant CCK-8 analogue, (pGlu-Gln)-CCK-8, in normal mice.. Journal of Endocrinology, 216 (1). pp. 53-59.

Irwin, Nigel, Montgomery, IA, O'Harte, Finbarr, Frizelle, P and Flatt, Peter (2012) Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes. International Journal of Obesity, 37 (8). pp. 1058-1063.

Irwin, Nigel, Frizelle, P, Montgomery, IA, Moffett, RC, O'Harte, Finbarr and Flatt, Peter (2012) Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. Diabetologia, 55 (10). pp. 2747-2758.

Venneti, KC, Malthouse, JP, O'Harte, Finbarr and Hewage, CM (2011) Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide.. Biochim Biophys Acta. , 1814 (7). pp. 882-888.

Bell, Partrick, Cuthbertson, Joy, Patterson, Steven and O'Harte, Finbarr (2011) Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes . DIABETES RESEARCH AND CLINICAL PRACTICE , 91 . pp. E68-E70.

O'Harte, Finbarr, Rafferty, E. P., Franklin, Z. and Irwin, Nigel (2010) (Pro(3))glucagon-amide acts as a glucagon receptor antagonist in cultured cells and in obese diabetic ob/ob mice. IRISH JOURNAL OF MEDICAL SCIENCE, 179 (13). pp. 507.

Hunter, Kerry, O'Harte, FPM, Abdel-Wahab, YHA and Flatt, PR (2010) Evaluation of the inhibitory action of islet amyloid polypeptide on insulin secretion from clonal rat pancreatic beta-cells. REGULATORY PEPTIDES, 164 (1, Sp. Iss. SI). pp. 44.

O'Harte, Finbarr, Franklin, Z, Rafferty, EP and Irwin, Nigel (2010) The novel (Pro(3)) glucagon-amide analogue antagonises the action of glucagon both in vitro and in vivo. REGULATORY PEPTIDES, 164 (1, Sp. Iss. SI). pp. 42.

Rafferty, EP, Franklin, Z, Irwin, Nigel and O'Harte, Finbarr (2010) Stability and efficacy studies in N-terminally truncated glucagon receptor antagonist peptides. REGULATORY PEPTIDES, 164 (1, Sp. Iss. SI). pp. 41-42.

Franklin, Z, Rafferty, EP, Irwin, Nigel and O'Harte, Finbarr (2010) Peptide based glucagon analogues are effective agents in blocking the hyperglycaemic actions of glucagon in high fat fed mice. REGULATORY PEPTIDES, 164 (1, Sp. Iss. SI). pp. 32-33.

Kerr, Barry D, Irwin, Nigel, O'Harte, Finbarr, Bailey, Clifford J, Flatt, Peter and Gault, Victor (2009) Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. BIOCHEMICAL PHARMACOLOGY, 78 (8). pp. 1008-1016.

McKillop, Aine, Duffy, NA, Lindsay, JR, Green, BD, Patterson, Steven, O'Harte, Finbarr, Bell, PM and Flatt, Peter (2009) Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.. European Journal of Endocrinology, 16 (6). pp. 877-885.

Gault, Victor, Kerr, BD, Irwin, Nigel, O'Harte, Finbarr and Flatt, Peter (2009) Fatty acid derivatised forms of glucose-dependent insulinotropic polypeptide with improved glucose-lowering and insulin-releasing properties. DIABETOLOGIA, 52 (Suppl. 1). pp. 786.

O'Harte, FPM, McClean, PL and Irwin, N (2009) Structure function studies with glucagon related peptides reveal glucagon receptor antagonist activities in vitro and in vivo. In: 45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes, Vienna. . 565

Cuthbertson, J, Patterson, S, O'Harte, FPM and Bell, PM (2009) Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. DIABETIC MEDICINE, 26 (6). pp. 649-654.

O'Harte, Finbarr, Kerr, BD, Irwin, Nigel, Gault, Victor and Flatt, Peter (2009) GIP(Lys37MYR), a novel acylated analogue of glucose-dependent insulinotropic polypeptide (GIP) has enhanced stability, glucose lowering and insulin releasing properties in obese diabetic (ob/ob) mice. Irish Journal of Medical Science, 178 (S10). pp. 389-389.

Cuthbertson, J, Patterson, Steven, O'Harte, FPM and Bell, PM (2008) Metformin combined with exogenous glucagon-like peptide-1 gives added benefit by improving acute glycaemic control in type 2 diabetic subjects. In: 44th Annual Meeting of the EASD , Rome. . 943

O'Harte, Finbarr, Frizelle, PA and Flatt, Peter (2008) Peripheral N-acetylated cholecystokinin-8 administration has more potent effect in reducing short term food intake than peptide YY in mice. DIABETOLOGIA, 51 (Suppl. 1). pp. 124.

McKillop, Aine, Duffy, Nicola A, Lindsay, John R, O'Harte, Finbarr, Bell, Patrick M and Flatt, Peter (2008) Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. DIABETES RESEARCH AND CLINICAL PRACTICE, 79 (1). pp. 79-85.

Irwin, Nigel, McClean, Paula, Cassidy, Roslyn S, O'Harte, Finbarr, Green, Brian D, Gault, Victor, Harriott, Patrick and Flatt, Peter (2007) Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. DIABETES-METABOLISM RESEARCH AND REVIEWS, 23 (7). pp. 572-579.

McKillop, Aine, Duffy, NA, Green, BD, Irwin, Nigel, Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2007) Antidiabetic action of nateglinide includes augmentation of glucagon-like peptide-1 activity mediated partly through inhibition of DPP IV mediated degradation. DIABETOLOGIA, 50 (Suppl. 1). pp. 0882.

O'Harte, Finbarr, Frizelle, PA and Flatt, Peter (2007) Enzyme resistant N-terminally modified cholecystokinin-8 exhibits enhanced satiety and insulinotrophism compared with exendin-4. DIABETOLOGIA, 50 (Suppl. 1). pp. 0585.

Hewage, CM, Alana, I and O'Harte, FPM (2007) Structural studies of glucose-dependent insulinotropic polypeptide (GIP) in micellular media. In: 43rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes, Amsterdam. . 0593

Duffy, Nicola A, Green, Brian D, Irwin, Nigel, Gault, Victor, McKillop, Aine, O'Harte, Finbarr and Flatt, Peter (2007) Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. EUROPEAN JOURNAL OF PHARMACOLOGY, 568 (1-3). pp. 278-286.

Irwin, Nigel, McClean, Paula, O'Harte, Finbarr, Gault, Victor, Harriott, P and Flatt, Peter (2007) Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. DIABETOLOGIA, 50 (7). pp. 1532-1540.

Alana, Inigo, Malthouse, J Paul G, O'Harte, Finbarr PM and Hewage, Chandralal M (2007) The bioactive conformation of glucose-dependent insulinotropic polypeptide by NMR and CD spectroscopy. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 68 (1). pp. 92-99.

O'Harte, Finbarr, Hunter, Kerry, Gault, Victor, Irwin, Nigel, Green, Brian D., Greer, Brett, Harriott, Patrick, Bailey, Clifford J. and Flatt, Peter (2007) Antagonistic effects of two novel GIP analogs, (Hyp(3))GIP and (Hyp(3)) GIPLys(16)PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 292 (6). pp. E1674-E1682.

Gault, Victor, Hunter, Kerry, Irwin, Nigel, Green, Brian D, Greer, Brett, Harriott, Patrick, O'Harte, Finbarr and Flatt, Peter (2007) Characterisation and biological activity of Glu(3) amino acid substituted GIP receptor antagonists. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 461 (2). pp. 263-274.

Irwin, Nigel, Parker, JC, Gault, Victor, Greer, B, Harriott, P, O'Harte, Finbarr and Flatt, Peter (2007) N-terminally truncated metabolite of glucose-dependent insulinotropic polypeptide (GIP) but not glucagon-like peptide-1 (GLP-1) improves glucose homeostasis in ob/ob mice through alleviation of insulin resistance. DIABETIC MEDICINE, 24 (Suppl. 1). pp. 22.

O'Harte, Finbarr, Irwin, Nigel, Gault, Victor, McClean, Paula, Cassidy, RS, Harriott, P and Flatt, Peter (2007) Antidiabetic effects of sub-chronic administration of stable incretin mimetics N-AcGIP and exendin-4 (1-39) amide in obese-diabetic mice. DIABETIC MEDICINE, 24 (Suppl. 1). pp. 22.

Gault, Victor, Hunter, Kerry, Irwin, Nigel, Greer, Brett, Green, Brian D, Harriott, Patrick, O'Harte, Finbarr and Flatt, Peter (2007) Characterisation and glucoregulatory actions of a novel acylated form of the (Pro(3))GIP receptor antagonist in type 2 diabetes. BIOLOGICAL CHEMISTRY, 388 (2). pp. 173-179.

Parker, Jeremy C, Irwin, Nigel, Lavery, Kerry S, Green, Brian D, O'Harte, Finbarr, Gault, Victor and Flatt, Peter (2007) Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro(3))GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice. BIOLOGICAL CHEMISTRY, 388 (2). pp. 221-226.

Mckillop, Aine, Duffy, Nicola, Lindsay, John, Green, Brian, O'Harte, Finbarr, Bell, Patrick and Flatt, Peter (2007) Effects of nateglinide on DPP-IV activity and incretin hormone degradation in type 2 diabetic patients. Irish Journal of Medical Science, 176. pp. S367.

Green, Brian D, Irwin, Nigel, Duffy, Nicola A, Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2006) Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. EUROPEAN JOURNAL OF PHARMACOLOGY, 547 (1-3). pp. 192-199.

Parker, JC, Lavery, KS, Irwin, Nigel, Green, BD, Greer, B, Harriott, P, O'Harte, Finbarr, Gault, Victor and Flatt, Peter (2006) Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1 (9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. JOURNAL OF ENDOCRINOLOGY, 191 (1). pp. 93-100.

Irwin, Nigel, Clarke, Gillian C, Green, Brian D, Greer, Brett, Harriott, Patrick, Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2006) Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. BIOCHEMICAL PHARMACOLOGY, 72 (6). pp. 719-728.

O'Harte, Finbarr, Hunter, K., Gault, Victor, Irwin, Nigel, Harriott, P. and Flatt, Peter (2006) Cellular and metabolic evaluation of (hydroxyproline(3))-GIP as new stable GIP receptor antagonist with antidiabetic potential. DIABETOLOGIA, 49 (Suppl. 1). pp. 0661.

Irwin, Nigel, Clarke, GC, Gault, Victor, Green, BD, Harriott, P, O'Harte, Finbarr and Flatt, Peter (2006) Long-acting analogues of GIP with significantly improved antihyperglycaemic and insulinotropic properties: N-terminal modification versus mid-chain acylation. DIABETOLOGIA, 49 (Suppl. 1). pp. 0172.

Flatt, Peter, Irwin, Nigel, McClean, Paula, Green, BD, Gault, Victor, Bailey, CJ and O'Harte, Finbarr (2006) Early administration of the GIP receptor antagonist (Pro(3))GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity. DIABETOLOGIA, 49 (Suppl. 1). pp. 0171.

Gault, Victor, Hunter, Kerry, Irwin, Nigel, Green, BD, O'Harte, Finbarr and Flatt, Peter (2006) Characterisation of novel glucose-dependent insulinotropic polypeptide (GIP) antagonists generated through amino acid substitution at position Glu(3). DIABETOLOGIA, 49 (Suppl. 1). pp. 0672.

McKillop, Aine, Duffy, NA, Lindsay, JR, Green, BD, O'Harte, Finbarr, Bell, PM and Flatt, Peter (2006) Insulinotropic actions of nateglinide are accompanied by inhibition of dipeptidyl peptidase-IV activity. DIABETOLOGIA, 49 (Suppl. 1). pp. 0796.

Green, Brian D, Lavery, Kerry S, Irwin, Nigel, O'Harte, Finbarr, Harriott, Patrick, Greer, Brett, Bailey, Clifford J and Flatt, Peter (2006) Novel glucagon-like peptide-1 (GLP-1) analog (Val(8))GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 318 (2). pp. 914-921.

Marenah, Lamin, McCluskey, Janie, Abdel-Wahab, Yasser, O'Harte, Finbarr, McClenaghan, Neville and Flatt, Peter (2006) A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL(16)), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. BIOLOGICAL CHEMISTRY, 387 (7). pp. 941-947.

Irwin, Nigel, Green, Brian D, Parker, Jeremy C, Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2006) Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro(3))GIP(1-16). REGULATORY PEPTIDES, 135 (1-2). pp. 45-53.

Alana, I, Parker, JC, Gault, Victor, Flatt, Peter, O'Harte, Finbarr, Malthouse, JPG and Hewage, CM (2006) NMR and alanine scan studies of glucose-dependent insulinotropic polypeptide in water. JOURNAL OF BIOLOGICAL CHEMISTRY, 281 (24). pp. 16370-16376.

Irwin, Nigel, Green, BD, Gault, Victor, Cassidy, RS, O'Harte, Finbarr, Harriott, P and Flatt, Peter (2006) Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL(37)) in normal mice. PEPTIDES, 27 (4). pp. 893-900.

Irwin, Nigel, O'Harte, Finbarr, Gault, Victor, Green, BD, Greer, B, Harriott, P, Bailey, CJ and Flatt, Peter (2006) GIP(Lys(16)PAL) and GIP(LyS(37)PAL): Novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. JOURNAL OF MEDICINAL CHEMISTRY, 49 (3). pp. 1047-1054.

McKillop, Aine, Lindsay, JR, Au, S, Mahood, KI, O'Harte, Finbarr, Flatt, Peter and Bell, PM (2006) Meal-dependent regulation of circulating glycated insulin in type 2 diabetic subjects. HORMONE AND METABOLIC RESEARCH, 38 (2). pp. 94-97.

Irwin, Nigel, Green, BD, Gault, Victor, Harriot, P, O'Harte, Finbarr and Flatt, Peter (2006) Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice. EXPERIMENTAL GERONTOLOGY, 41 (2). pp. 151-156.

Irwin, Nigel, Gault, Victor, Green, BD, Greer, B, Harriott, P, Bailey, CJ, O'Harte, Finbarr and Flatt, Peter (2006) Novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide (GIP) with enhanced antihyperglycaemic and insulinotropic properties. Diabetic Medicine, 23 (S2). pp. 8-8.

O'Harte, Finbarr, Irwin, Nigel, Green, BD, Gault, Victor, Cassidy, RS, Harriott, P and Flatt, Peter (2006) Administration of fatty acid linked glucose-dependent insulinotropic polypeptide receptor antagonist for two weeks improves glucose tolerance in normal mice. Diabetic Medicine , 23 (S2). pp. 22-22.

Gault, Victor, Irwin, Nigel, Green, BD, O'Harte, Finbarr and Flatt, Peter (2006) Long-acting glucose-dependent insulinotropic polypeptide (GIP) receptor agonist restores beta-cell glucose responsiveness in ageing mice. Diabetic Medicine , 23 (S2). pp. 31-31.

Alana, I, Parker, JC, Gault, Victor, O'Harte, Finbarr, Malthouse, JP and Hewage, C (2006) NMR and modelling studies of glucose-dependent insulinotropic polypeptide (GIP). Journal of Peptide Science, 12. pp. 185-185.

Green, BD, Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2005) A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. DIABETES OBESITY AND METABOLISM, 7 (5). pp. 595-604.

Green, BD, Liu, HK, McCluskey, Janie, Duffy, NA, O'Harte, Finbarr, McClenaghan, Neville and Flatt, Peter (2005) Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1. DIABETES OBESITY AND METABOLISM, 7 (5). pp. 563-569.

Irwin, Nigel, Green, BD, Mooney, MH, Greer, B, Harriott, P, Bailey, CJ, Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2005) A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 314 (3). pp. 1187-1194.

Gault, Victor, Irwin, Nigel, Green, BD, McCluskey, Janie, Greer, B, Bailey, CJ, Harriott, P, O'Harte, Finbarr and Flatt, Peter (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro(3))GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. DIABETES, 54 (8). pp. 2436-2446.

Irwin, Nigel, Gault, Victor, Green, BD, Greer, B, Harriott, P, Bailey, CJ, O'Harte, Finbarr and Flatt, Peter (2005) Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL(16)) and N-AcGIP(LysPAL(37)). BIOLOGICAL CHEMISTRY, 386 (7). pp. 679-687.

Hewage, CM, Alana, I, O'Harte, FP and Malthouse, JP (2005) Structural studies of the glucose-dependent insulinotropic polypeptide (GIP) by NMR and molecular modeling. In: IUBMB 50th Anniversary Symposium. . 373

Lindsay, JR, Duffy, NA, McKillop, Aine, Ardill, J, O'Harte, Finbarr, Flatt, Peter and Bell, PM (2005) Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. DIABETIC MEDICINE, 22 (5). pp. 654-657.

Green, BD, Irwin, Nigel, Gault, Victor, Bailey, CJ, O'Harte, Finbarr and Flatt, Peter (2005) Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice. JOURNAL OF ENDOCRINOLOGY, 185 (2). pp. 307-317.

Irwin, Nigel, Green, BD, Gault, Victor, Greer, B, Harriott, P, Bailey, CJ, Flatt, Peter and O'Harte, Finbarr (2005) Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. JOURNAL OF MEDICINAL CHEMISTRY, 48 (4). pp. 1244-1250.

Green, Brian, Irwin, Nigel, Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2005) Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. The British Journal of Diabetes and Vascular Disease , 5. pp. 134-140.

Lavery, KS, Green, BD, Parker, JC, Irwin, Nigel, Gault, Victor, Flatt, Peter and O'Harte, Finbarr (2005) The truncated peptide glucagon-like peptide-1(9-36)amide has no insulin releasing activity but retains a significant effect on glucose disposal in vitro and in vivo. Diabetic Medicine, 22 (S2). pp. 17-17.

O'Harte, Finbarr, Irwin, Nigel, Green, BD, Harriott, P, Greer, B, Gault, Victor and Flatt, Peter (2005) Once daily administration of (Pro3)GIP ameliorates glucose intolerance and improves insulin sensitivity in obese diabetic (ob/ob) mice.. Irish Journal of Medical , 174 (S2). pp. 8-8.

Furman, B, Pyne, N, Flatt, Peter and O'Harte, Finbarr (2004) Targeting beta-cell cyclic 3 ` 5 ` adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. JOURNAL OF PHARMACY AND PHARMACOLOGY, 56 (12). pp. 1477-1492.

Gault, Victor, Irwin, Nigel, O'Harte, Finbarr, Green, BD and Flatt, Peter (2004) Antidiabetic potential of a long-acting derivative of GIP following once daily administration in type 2 diabetes. REGULATORY PEPTIDES, 122 (1). pp. A55.

O'Harte, Finbarr, Irwin, Nigel, Gault, Victor, Green, BD and Flatt, Peter (2004) Assessment of the antidiabetic potential of two fatty acid derivatized GIP analogues. REGULATORY PEPTIDES, 122 (1). pp. A105.

Irwin, Nigel, Gault, Victor, Green, BD, Greer, B, McCluskey, Janie, Harriott, P, O'Harte, Finbarr and Flatt, Peter (2004) Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. BIOLOGICAL CHEMISTRY, 385 (9). pp. 845-852.

McKillop, Aine, Duffy, N, Lindsay, JR, Flatt, Peter, Bell, PM and O'Harte, Finbarr (2004) Decreased dipeptidyl peptidase-IV activity and degradation of glucagon-like peptide-1(7-36)amide in Type 2 diabetes. DIABETOLOGIA, 47 (Suppl. 1). pp. 792.

Irwin, Nigel, Gault, Victor, Green, BD, Harriott, P, O'Harte, Finbarr and Flatt, Peter (2004) Long-acting Tyr(1)-modified analogues of GIP with significantly improved antihyperglycaemic and insulinotropic properties. DIABETOLOGIA, 47 (Suppl. 1). pp. 109.

Green, BD, Irwin, Nigel, Gault, Victor, O'Harte, Finbarr, Bailey, CJ and Flatt, Peter (2004) Chronic treatment of obese hyperglycaemic ob/ob mice with exendin(9-39)amide suggests a minor role for endogenous GLP-1 in metabolic abnormalities of obesity-diabetes. DIABETOLOGIA, 47 (Suppl. 1). pp. 659.

Green, BD, Gault, Victor, Flatt, Peter, Harriott, P, Greer, B and O'Harte, Finbarr (2004) Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala(8)/Ala(2) with 2-aminobutyric acid. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 428 (2). pp. 136-143.

Green, BD, Mooney, MH, Gault, Victor, Irwin, Nigel, Bailey, CJ, Harriott, P, Greer, B, O'Harte, Finbarr and Flatt, Peter (2004) N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. JOURNAL OF ENDOCRINOLOGY, 180 (3). pp. 379-388.

Green, BD, Gault, Victor, Mooney, MH, Irwin, Nigel, Harriott, P, Greer, B, Bailey, CJ, O'Harte, Finbarr and Flatt, Peter (2004) Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala(8)-substituted GLP-1 analogues. BIOLOGICAL CHEMISTRY, 385 (2). pp. 169-177.

Green, BD, Mooney, MH, Gault, Victor, Irwin, Nigel, Bailey, CJ, Harriott, P, Greer, B, Flatt, Peter and O'Harte, Finbarr (2004) Lys(9) for Glu(9) substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). METABOLISM-CLINICAL AND EXPERIMENTAL, 53 (2). pp. 252-259.

Green, BD, Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2004) Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypcptide (GIP) as future antidiabetic agents. CURRENT PHARMACEUTICAL DESIGN, 10 (29). pp. 3651-3662.

Liu, HK, Green, BD, Gault, Victor, McCluskey, Janie, McClenaghan, Neville, O'Harte, Finbarr and Flatt, Peter (2004) N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression. CELL BIOLOGY INTERNATIONAL, 28 (1). pp. 69-73.

Green, BD, Gault, Victor, Mooney, MH, Irwin, Nigel, Harriott, P, Greer, B, O'Harte, Finbarr and Flatt, Peter (2004) Molecular, cellular and biological characteristics of DPP IV-resistant acetylated analogues of GLP-1. . Diabetic Medicine, 21 (S2). pp. 26-26.

Gault, Victor, Green, BD, Irwin, Nigel, Harriott, P, Greer, B, Flatt, Peter and O'Harte, Finbarr (2004) Development and characterisation of novel N-terminal Glu9-substituted agonists of glucagon-like peptide-1 (GLP-1). Diabetic Medicine, 21 (S2). pp. 26-26.

Flatt, Peter, Irwin, Nigel, Green, BD, Harriott, P, Gault, Victor and O'Harte, Finbarr (2004) Daily administration of GIP receptor antagonist alleviates glucose intolerance and counters insulin resistance in an animal model of obesity and type 2 diabetes. Diabetologia, 47 (S1). pp. 282-282.

McCluskey, Janie, Irwin, Nigel, Gault, Victor, Green, BD, Flatt, Peter and O'Harte, Finbarr (2004) Longer-term ablation of GIP signalling in normal mice demonstrates importance of GIP for glucose homeostasis as part of the enteroinsular axis. Proceedings of the EASD Islet Study Group, Meeting on Molecular Aspects of Pancreatic Islet Function, 1. pp. 26-26.

Hunter, Kerry, Irwin, Nigel, Green, BD, Flatt, Peter, O'Harte, Finbarr and Gault, Victor (2004) Novel long-acting enzyme-resistant glucose-dependent insulinotropic polypeptide receptor agonists with improved antihyperglycaemic and insulinotropic activity. Irish Journal of Medical Science, 173 (S1). pp. 35-35.

Alana, I, Hewage, CM, Malthouse, JP, Parker, JC, Gault, Victor and O'Harte, Finbarr (2004) NMR structure of the glucose-dependent insulinotropic polypeptide fragment, GIP(1-30)amide. Biochemical and Biophysical Research Communications , 325. pp. 281-286.

O'Harte, Finbarr, Irwin, Nigel, Gault, Victor, Green, BD and Flatt, Peter (2004) C-16 fatty acid derivatised GIP analogues as potential agents for diabetes therapy. Irish Journal of Medical Science, 173 (S1). pp. 10-10.

O'Harte, Finbarr, Green, BD, Gault, Victor, Irwin, Nigel, Mooney, MH, Harriott, P, Greer, B and Flatt, Peter (2004) (Lys9)GLP-1 lacks insulinotropic activity but acts as a potent novel GLP-1 receptor antagonist in vivo. Diabetic Medicine, 21 (S2). pp. 43-43.

Mckillop, Aine, Lindsay, John, O'Harte, Finbarr, Bell, Patrick and Flatt, Peter (2004) Meal and glucose-dependent insulinotropic polypeptide regulation of circulating glycated insulin in type 2 diabetic subjects. . Diabetic Medicine, 21. pp. 6-7.

Green, BD, Gault, Victor, Irwin, Nigel, Mooney, MH, Bailey, CJ, Harriott, P, Greer, B, Flatt, Peter and O'Harte, Finbarr (2003) Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu(9)-substituted analogues of glucagon-like peptide-1. BIOLOGICAL CHEMISTRY, 384 (12). pp. 1543-1551.

Green, BD, Gault, Victor, Mooney, MH, Irwin, Nigel, Bailey, CJ, Harriott, P, Greer, B, Flatt, Peter and O'Harte, Finbarr (2003) Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. JOURNAL OF MOLECULAR ENDOCRINOLOGY, 31 (3). pp. 529-540.

Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2003) Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?. NEUROPEPTIDES, 37 (5). pp. 253-263.

Lindsay, JR, McKillop, Aine, Mooney, MH, O'Harte, Finbarr, Flatt, Peter and Bell, PM (2003) Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes. DIABETES RESEARCH AND CLINICAL PRACTICE, 61 (3). pp. 167-173.

Gault, Victor, Flatt, Peter and O'Harte, Finbarr (2003) Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 308 (2). pp. 207-213.

Gault, Victor, O'Harte, Finbarr, Harriott, P and Flatt, Peter (2003) Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala(2)-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. METABOLISM-CLINICAL AND EXPERIMENTAL, 52 (6). pp. 679-687.

Lindsay, JR, McKillop, Aine, Mooney, MH, Flatt, Peter, Bell, PM and O'Harte, Finbarr (2003) Meal-induced 24-hour profile of circulating glycated insulin in type 2 diabetic subjects measured by a novel radioimmunoassay. METABOLISM-CLINICAL AND EXPERIMENTAL, 52 (5). pp. 631-635.

McKillop, Aine, Meade, A, Flatt, Peter and O'Harte, Finbarr (2003) Evaluation of the site(s) of glycation in human proinsulin by ion-trap LCQ electrospray ionization mass spectrometry. REGULATORY PEPTIDES, 113 (1-3). pp. 1-8.

Lindsay, JR, McKillop, Aine, Mooney, MH, O'Harte, Finbarr, Bell, PM and Flatt, Peter (2003) Demonstration of increased concentrations of circulating glycated insulin in human Type 2 diabetes using a novel and specific radioimmunoassay. DIABETOLOGIA, 46 (4). pp. 475-478.

Gault, Victor, O'Harte, Finbarr, Harriott, P, Mooney, MH, Green, BD and Flatt, Peter (2003) Effects of the novel (Pro(3))GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. DIABETOLOGIA, 46 (2). pp. 222-230.

Hunter, SJ, Boyd, AC, O'Harte, Finbarr, McKillop, Aine, Wiggam, MI, Mooney, MH, McCluskey, Janie, Lindsay, JR, Ennis, CN, Gamble, R, Sheridan, B, Barnett, CR, McNulty, Helene, Bell, PM and Flatt, Peter (2003) Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans. DIABETES, 52 (2). pp. 492-498.

Gault, Victor, Flatt, Peter, Harriott, P, Mooney, MH, Bailey, CJ and O'Harte, Finbarr (2003) Improved biological activity of Gly(2)- and Ser(2)-substituted analogues of glucose-dependent insulinotrophic polypeptide. JOURNAL OF ENDOCRINOLOGY, 176 (1). pp. 133-141.

Gault, Victor, Irwin, Nigel, Harriott, P, Flatt, Peter and O'Harte, Finbarr (2003) DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser(2)-Asp(13))GIP. CELL BIOLOGY INTERNATIONAL, 27 (1). pp. 41-46.

Irwin, Nigel, Green, BD, Lui, HK, McCluskey, Janie, McClenaghan, Neville, Gault, Victor, Harriott, P, Greer, B, O'Harte, Finbarr and Flatt, Peter (2003) Dipeptidylpeptidase IV-resistant glucagon-like peptide-1(7-36)amide analogue N-acetyl-GLP-1 has improved effects on pancreatic beta-cell associated gene expression. Irish Journal of Medical Science, 172 (S1). pp. 24-24.

O'Harte, Finbarr, Gault, Victor, Harriott, P, Irwin, Nigel, Mooney, MH and Flatt, Peter (2003) Biological activity of two novel N-terminal Ala2-substituted analogues of glucose-dependent insulinotropic polypeptide. Diabetic Medicine, 20 (S2). pp. 35-35.

Green, BD, Gault, Victor, Monney, MH, Irwin, Nigel, Harriott, P, Greer, B, O'Harte, Finbarr and Flatt, Peter (2003) Dipeptidylpeptidase IV degradation, receptor binding, insulin-secreting and antihyperglycaemic characteristics of palmitate-derivitised glucagon-like peptide-1(7-36)amide analogues. Irish Journal of Medical Science, 172 (S1). pp. 41-41.

Irwin, Nigel, Gault, Victor, Flatt, Peter, Mooney, MH and O'Harte, Finbarr (2003) Biological activity of mono- and di-substituted analogues of gastric inhibitory polypeptide (GIP). Proceedings of BioNet Annual Conference, 1. pp. 28-28.

O'Harte, Finbarr, Green, BD, Mooney, MH, Gault, Victor, Irwin, Nigel, Harriott, P, Greer, B and Flatt, Peter (2003) Comparison of the activity of the novel dipeptidylpeptidase IV-resistant GLP-1 receptor antagonist (Lys9)GLP-1 with GLP-1(9-36)amide and exendin-4(9-39). Irish Journal of Medical Science, 172 (S1). pp. 10-10.

Gault, Victor, Parker, JC, Harriott, P, Mooney, MH, Flatt, Peter and O'Harte, Finbarr (2003) Major metabolite of glucose-dependent insulinotropic polypeptide (GIP), GIP(3-42), acts as a GIP receptor antagonist in vivo. . Diabetic Medicine, 20 (S2). pp. 36-36.

Mooney, MH, Gault, Victor, Harriott, P, Flatt, Peter and O'Harte, Finbarr (2003) Fragment peptides reveal bioactive domains critical for insulin-releasing activity of glucose-dependent insulinotropic polypeptide. Diabetic Medicine, 20 (S2). pp. 35-35.

Green, BD, Gault, Victor, Harriott, P, Greer, B, Mooney, MH, Flatt, Peter and O'Harte, Finbarr (2003) Stability, cAMP production, insulin secretion and antihyperglycaemic activity of Pro3-substituted analogues of GLP-1 and GIP. Diabetic Medicine, 20 (S2). pp. 36-36.

Lindsay, John, Duffy, Nicola, Mckillop, Aine, Ardill, Joy, O'Harte, Finbarr, Flatt, Peter and Bell, Patrick (2003) Inhibition of dipeptidyl peptidase IV (DPP-IV) activity by oral metformin in type 2 diabetes. Diabetic Medicine, 20. pp. 4-5.

Mckillop, Aine, Duffy, Nicola, Lindsay, John, O'Harte, Finbarr and Flatt, Peter (2003) Decreased activity of dipeptidyl peptidase-IV potentially enhances glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide. . Diabetic Medicine, 20. pp. 37.

McKillop, Aine, Abdel-Wahab, Yasser, Mooney, MH, O'Harte, Finbarr and Flatt, Peter (2002) Secretion of glycated insulin from pancreatic beta-cells in diabetes represents a novel aspect of beta-cell dysfunction and glucose toxicity. DIABETES AND METABOLISM, 28 (6, Part 2). pp. S61-S69.

Gault, Victor, Harriott, P, Flatt, Peter and O'Harte, Finbarr (2002) Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide. BIOSCIENCE REPORTS, 22 (5-6). pp. 523-528.

Gault, Victor, Flatt, Peter, Bailey, CJ, Harriott, P, Greer, B, Mooney, MH and O'Harte, Finbarr (2002) Enhanced cAMP generation and insulin-releasing potency of two novel Tyr(1)-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. BIOCHEMICAL JOURNAL, 367 (Part 3). pp. 913-920.

Gault, Victor, Parker, JC, Harriott, P, Flatt, Peter and O'Harte, Finbarr (2002) Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. JOURNAL OF ENDOCRINOLOGY, 175 (2). pp. 525-533.

O'Harte, Finbarr, Gault, Victor, Parker, JC, Harriott, P, Mooney, MH, Bailey, CJ and Flatt, Peter (2002) Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. DIABETOLOGIA, 45 (9). pp. 1281-1291.

O'Harte, Finbarr, Gault, Victor, Harriott, P, Green, BD and Flatt, Peter (2002) Comparative studies with exendin(9-39)amide and the novel (Pro(3))GIP receptor antagonist indicates that glucose-dependent insulinotropic polypeptide is the major hormone of the enteroinsular axis. DIABETOLOGIA, 45 (Suppl. 2). pp. 548.

McKillop, Aine, Lindsay, JR, Mooney, MH, O'Harte, Finbarr, Bell, PM and Flatt, Peter (2002) Electrospray ionization mass spectrometry characterisation and measurement of circulating glycated insulin and responses to fasting and feeding in Type 2 diabetic subjects. DIABETOLOGIA, 45 (Suppl. 2). pp. 1221.

Green, BD, O'Harte, Finbarr, Greer, B, Harriott, P and Flatt, Peter (2002) Enhanced plasma stability, receptor binding, cyclic-amp production and insulin-releasing activity of two novel penultimate N-termnially substituted analogues of glucagon-like peptide-1. DIABETOLOGIA, 45 (Suppl. 2). pp. 486.

Gault, Victor, Green, BD, Greer, B, Harriott, P, Flatt, Peter and O'Harte, Finbarr (2002) N-terminally modified analogues of glucose-dependent insulinotropic polypeptide exhibit improved insulinotropic activity and antihyperglycaemic potential compared with glucagon-like peptide-1 counterparts. DIABETOLOGIA, 45 (Suppl. 2). pp. 545.

Flatt, Peter, Gault, Victor, Harriott, P, Greer, B, Mooney, MH, Bailey, CJ and O'Harte, Finbarr (2002) Novel N-Fmoc and N-palmitate analogues of glucose-dependent insullinotropic polypeptide exhibit DPP IV resistance, increased insulin-releasing activity and antidiabetic action.. DIABETOLOGIA, 45 (Suppl. 2). pp. 546.

Mooney, MH, Gault, Victor, Flatt, Peter, Harriott, P, Greer, B, Bailey, CJ and O'Harte, Finbarr (2002) Antidiabetic potential of four novel analogues of glucose-dependent insulinotropic polypeptide demonstrated in an animal model of Type 2 diabetes. DIABETOLOGIA, 45 (Suppl. 2). pp. 547.

Lindsay, JR, Au, STB, Kelly, CM, O'Harte, Finbarr, Flatt, Peter and Bell, PM (2002) A novel amino-terminally glycated analogue of glucose-dependent insulinotropic polypeptide (GIP), with prolonged insulinotropic activity in type 2 diabetes mellitus. DIABETES, 51 (Suppl. 2). pp. 1394.

Abdel-Wahab, Yasser, O'Harte, Finbarr, Mooney, MH, Barnett, CR and Flatt, Peter (2002) Vitamin C supplementation decreases insulin glycation and improves glucose homeostasis in obese hyperglycemic (ob/ob) mice. METABOLISM-CLINICAL AND EXPERIMENTAL, 51 (4). pp. 514-517.

Gault, Victor, O'Harte, Finbarr, Harriott, P and Flatt, Peter (2002) Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 290 (5). pp. 1420-1426.

Mooney, MH, Abdel-Wahab, Yasser, McKillop, Aine, O'Harte, Finbarr and Flatt, Peter (2002) Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1569 (1-3). pp. 75-80.

Mooney, MH, Gault, Victor, Flatt, Peter, Harriott, P and O'Harte, Finbarr (2002) N-terminally modified degradation resistant analogues of glucose-dependent insulinotropic polypeptide display enhanced antidiabetic action.. Irish Journal of Medical Science, 171 (S3). pp. 9-9.

O'Harte, Finbarr, Gault, Victor, Harriott, H, Green, BD and Flatt, Peter (2002) Receptor antagonist studies indicate that GIP is a more important enteroinsular axis hormone than GLP-1 in obese diabetic (ob/ob) mice. Irish Journal of Medical Science, 171 (S3). pp. 18-18.

Lindsay, John, Duffy, Nicola, Mckillop, Aine, Ardill, Joy, O'Harte, Finbarr, Flatt, Peter and Bell, Patrick (2002) Metformin inhibits dipeptidyl peptidase IV activity in type 2 diabetes. Irish Journal of Medical Science, 171. pp. 29.

Mckillop, Aine, Lindsay, John, Mooney, Mark, Flatt, Peter, Bell, John and O'Harte, Finbarr (2002) Detection, isolation and fluctuation of glycated insulin in type 2 diabetic subjects. Irish Journal of Medical Science, 171. pp. 31.

Lindsay, John, Mckillop, Aine, Mooney, Mark, O'Harte, Finbarr, Flatt, Peter and Bell, Patrick (2002) Demonstration of diurnal variation of plasma glycated insulin in type 2 diabetes.. Endocrine Abstracts, 3. pp. 85.

Lindsay, John, Mckillop, Aine, Mooney, Mark, O'Harte, Finbarr, Bell, Patrick and Flatt, Peter (2002) Elevated plasma glycated insulin in type 2 diabetes, detected using a novel radioimmunoassay.. Diabetic Medicine, 19. pp. 182.

Mooney, MH, Abdel-Wahab, Yasser, Morgan, LM, O'Harte, Finbarr and Flatt, Peter (2001) Detection of glycated gastric inhibitory polypeptide within the intestines of diabetic obese (ob/ob) mice. ENDOCRINE, 16 (3). pp. 167-171.

McKillop, Aine, Mooney, MH, Harriott, P, Flatt, Peter and O'Harte, Finbarr (2001) Evaluation of glycated insulin in diabetic animals using immunocytochemistry and radioimmunoassay. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 286 (3). pp. 524-528.

O'Harte, Finbarr, Gault, Victor, Harriott, P, Parker, JC and Flatt, Peter (2001) DPP IV resistant N-terminally modified GIP analogues with enhanced insulinotropic activity. DIABETOLOGIA, 44 (Suppl. 1). pp. 746.

McKillop, Aine, Mooney, MH, O'Harte, Finbarr and Flatt, Peter (2001) Evaluation of glycated insulin in plasma and biological tissues of diabetic animal models. DIABETOLOGIA, 44 (Suppl. 1). pp. 1222.

Flatt, Peter, Gault, Victor, Harriott, P and O'Harte, Finbarr (2001) Antagonist actions of novel (Pro(3))GIP analogue and GIP(3-42) on cyclic AMP production and insulin secretion. DIABETOLOGIA, 44 (Suppl. 1). pp. 748.

Mooney, MH, Gault, Victor, Abdel-Wahab, Yasser, Flatt, Peter and O'Harte, Finbarr (2001) Identification of Tyr(1)-glucitol GIP in intestines of diabetic mice with enhanced insulin-releasing activity. DIABETOLOGIA, 44 (Suppl. 1). pp. 1223.

Gault, Victor, Harriott, P, Flatt, Peter and O'Harte, Finbarr (2001) GIP analogues substituted at Ala(2) exhibit improved plasma stability and insulin-releasing activity. DIABETOLOGIA, 44 (Suppl. 1). pp. 747.

O'Harte, Finbarr, Mooney, MH, Kelly, CMN, McKillop, Aine and Flatt, Peter (2001) Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice. REGULATORY PEPTIDES, 96 (3). pp. 95-104.

Mooney, MH, Flatt, Peter, Gault, Victor and O'Harte, Finbarr (2001) Detection of glycated glucose dependent insulinotropic polypeptide in the intestines of diabetic mice and assessment of its biological activity in vitro. . Irish Journal of Medical Science, 170 (S2). pp. 11-11.

O'Harte, Finbarr, Gault, Victor, Harriott, P, Parker, JC and Flatt, Peter (2001) Stable amino terminally-modified analogues of glucose-dependent insulinotropic polypeptide with improved insulin-releasing activity. . Irish Journal of Medical Science, 170 (S2). pp. 10-10.

Mckillop, Aine, Meade, Angela, Flatt, Peter and O'Harte, Finbarr (2001) Structural characterisation of glycated proinsulin. Irish Journal of Medical Science . Irish Journal of Medical Science, 170. pp. 11.

Lindsay, John, Mckillop, Aine, Mooney, Mark, O'Harte, Finbarr, Flatt, Peter and Bell, Patrick (2001) Detection of glycated insulin in plasma of type 2 diabetic subjects using a novel radioimmunoassay.. Irish Journal of Medical Science, 170. pp. 10.

McKillop, Aine, McCluskey, Janie, Boyd, AC, Mooney, MH, Flatt, Peter and O'Harte, Finbarr (2000) Production and characterization of specific antibodies for evaluation of glycated insulin in plasma and biological tissues. JOURNAL OF ENDOCRINOLOGY, 167 (1). pp. 153-163.

O'Harte, Finbarr, Boyd, AC, McKillop, Aine, Abdel-Wahab, Yasser, McNulty, Helene, Barnett, CR, Conlon, JM, Hojrup, P and Flatt, Peter (2000) Structure, antihyperglycemic activity and cellular actions of a novel diglycated human insulin. PEPTIDES, 21 (10). pp. 1519-1526.

Boyd, AC, Abdel-Wahab, Yasser, McKillop, Aine, McNulty, Helene, Barnett, CR, O'Harte, Finbarr and Flatt, Peter (2000) Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1523 (1). pp. 128-134.

O'Harte, Finbarr, McKillop, Aine, Mooney, MH and Flatt, Peter (2000) Development and use of a specific radioimmunoassay for detection of glycated insulin in diabetes. DIABETOLOGIA, 43 (Suppl. 1). pp. 208.

O'Harte, Finbarr, Mooney, MH, Kelly, CMN and Flatt, Peter (2000) Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. JOURNAL OF ENDOCRINOLOGY, 165 (3). pp. 639-648.

O'Harte, Finbarr, Mooney, MH, Lawlor, A and Flatt, Peter (2000) N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1474 (1). pp. 13-22.

Abdel-Wahab, Yasser, O'Harte, Finbarr, Mooney, MH, Conlon, JM and Flatt, Peter (1999) N-terminal glycation of cholecystokinin-8 abolishes its insulinotropic action on clonal pancreatic B-cells. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1452 (1). pp. 60-67.

Abdel-Wahab, Yasser, Mooney, MH, O'Harte, Finbarr and Flatt, Peter (1999) N-terminal glycation of CCK-8 abolishes its insulinotropic action on clonal B-cells. DIABETOLOGIA, 42 (Suppl. 1). pp. 545.

O'Harte, Finbarr, Mooney, MH, Kelly, CMN and Flatt, Peter (1999) Improved stability and glycaemic control with His(7)-glucitol glucagon-like peptide-1 in normal and diabetic rodents. DIABETOLOGIA, 42 (Suppl. 1). pp. 745.

O'Harte, Finbarr, Mooney, MH and Flatt, Peter (1999) NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. DIABETES, 48 (4). pp. 758-765.

Gault, Victor, Harriott, P, Flatt, Peter and O'Harte, Finbarr (1999) Stability of GIP and amino terminally modified GIP analogues to DPP IV and human plasma. Digestion, 60. pp. 504-504.

O'Harte, Finbarr, Abdel-Wahab, Yasser, Conlon, JM and Flatt, Peter (1998) Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1425 (2). pp. 319-327.

O'Harte, Finbarr, Abdel-Wahab, Yasser, Conlon, JM and Flatt, Peter (1998) Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells. DIABETOLOGIA, 41 (10). pp. 1187-1193.

O'Harte, Finbarr, Mooney, MH, Kelly, CMN and Flatt, Peter (1998) Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. DIABETES, 47 (10). pp. 1619-1624.

Conlon, JM, Abdel-Wahab, Yasser, O'Harte, FPM, Nielsen, PF and Whittaker, J (1998) Purification and characterization of insulin, glucagon, and two glucagon-like peptides with insulin-releasing activity from the pancreas of the toad, Bufo marinus. ENDOCRINOLOGY, 139 (8). pp. 3442-3448.

Mooney, M, Kelly, CMN, Flatt, Peter and O'Harte, Finbarr (1998) Aminopeptidase resistant glycated glucagon-like peptide-1[7-36]amide shows potent insulinotropic action in vivo.. DIABETOLOGIA, 41 (Suppl. 1). pp. 713.

O'Harte, Finbarr, Mooney, M and Flatt, Peter (1998) Glycated gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced insulinotropic activity.. DIABETOLOGIA, 41 (Suppl. 1). pp. 712.

O'Harte, Finbarr, Abdel-Wahab, Yasser, Conlon, JM and Flatt, Peter (1998) Glycated IAPP shows a reduced inhibitory action on insulin secretion.. BIOCHEMICAL SOCIETY TRANSACTIONS, 26 (1). pp. S6.

O'Harte, Finbarr, Gray, Alison and Flatt, Peter (1998) Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. JOURNAL OF ENDOCRINOLOGY, 156 (2). pp. 237-243.

Abdel-Wahab, Yasser, O'Harte, Finbarr, Barnett, CR and Flatt, Peter (1997) Characterization of insulin glycation in insulin-secreting cells maintained in tissue culture. JOURNAL OF ENDOCRINOLOGY, 152 (1). pp. 59-67.

Abdel-Wahab, Yasser, O'Harte, Finbarr, Boyd, AC, Barnett, CR and Flatt, Peter (1997) Glycation of insulin results in reduced biological activity in mice. ACTA DIABETOLOGICA, 34 (4). pp. 265-270.

Boyd, AC, O'Harte, FPM, Gray, Alison, Abdel-Wahab, Yasser, Barnett, CR and Flatt, Peter (1997) Mono- and di-glycated insulin exhibit reduced cellular glucose uptake and glucose lowering activity in mice.. Proceedings of the Nutrition Society, 56 (1A). pp. 43A.

O'Harte, FPM, Gray, Alison, Abdel-Wahab, Yasser and Flatt, Peter (1997) Effects of glycated and non-glycated gastric inhibitory polypeptide on glucose transport and metabolism in isolated mouse abdominal muscle.. Proceedings of the Nutrition Society, 56 (1A). pp. 42A.

O'Harte, Finbarr, Gallagher, Alison, Abdel-Wahab, Yasser and Flatt, Peter (1997) Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle. PEPTIDES, 18 (9). pp. 1327-1333.

McClenaghan, Neville, Barnett, CR, O'Harte, Finbarr and Flatt, Peter (1996) Mechanisms of amino acid-induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B-cell line. JOURNAL OF ENDOCRINOLOGY, 151 (3). pp. 349-357.

Abdel-Wahab, Yasser, O'Harte, Finbarr, Ratcliff, H, McClenaghan, Neville, Barnett, CR and Flatt, Peter (1996) Glycation of insulin in the islets of Langerhans of normal and diabetic animals. DIABETES, 45 (11). pp. 1489-1496.

Boyd, AC, O'Harte, Finbarr, Gallagher, Alison, Abdel-Wahab, Yasser, McNulty, Helene, Barnett, CR and Flatt, Peter (1996) Reduced biological potency of mono-glycated insulin in vitro and in vivo in mice. DIABETOLOGIA, 39 (Suppl. 1). pp. 83.

McClenaghan, Neville, Barnett, CR, AhSing, E, Abdel-Wahab, Yasser, O'Harte, Finbarr, Yoon, TW, SwanstonFlatt, SK and Flatt, Peter (1996) Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. DIABETES, 45 (8). pp. 1132-1140.

Abdel-Wahab, Yasser, O'Harte, Finbarr, Gallagher, Alison and Flatt, Peter (1996) Glycation of GLP-1[7-36]amide but not GIP reduces its insulinotropic action in vitro. DIABETOLOGIA, 39 (Suppl. 1). pp. 84.

O'Harte, Finbarr, Gallagher, Alison, Abdel-Wahab, Yasser and Flatt, Peter (1996) Effects of glycated and non-glycated GLP-1[7-36]amide on glucose metabolism in muscle. DIABETOLOGIA, 39 (Suppl. 1). pp. 82.

McClenaghan, Neville, Barnett, CR, O'Harte, Finbarr, SwanstonFlatt, SK, AhSing, E and Flatt, Peter (1996) Characteristics of BRIN-BG5 and BRIN-BG7, two novel glucose-responsive insulin-secreting cell lines produced by electrofusion. JOURNAL OF ENDOCRINOLOGY, 148 (3). pp. 409-417.

O'Harte, Finbarr, Hojrup, P, Barnett, CR and Flatt, Peter (1996) Identification of the site of glycation of human insulin. PEPTIDES, 17 (8). pp. 1323-1330.

Flatt, Peter, O'Harte, Finbarr, Abdel-Wahab, Yasser, McClenaghan, Neville and Barrnett, CR (1995) GLYCATION OF INSULIN AND PROINSULIN OCCURS IN THE ISLETS OF LANGERHANS OF DIABETIC ANIMALS. DIABETOLOGIA, 38 (Suppl. 1). pp. A92.

O'Harte, Finbarr, Hunter, SJ, Boyd, AC, Wiggan, I, Ennis, CN, Gamble, R, Sheridan, B, Barnett, CR, McNulty, Helene, BELL, PM and Flatt, Peter (1995) DETERMINATION OF THE SITE OF GLYCATION OF HUMAN INSULIN AND BIOLOGICAL POTENCY USING EUGLYCEMIC CLAMPS IN MAN. DIABETOLOGIA, 38 (Suppl. 1). pp. A161.

O'Harte, Finbarr, Boyd, AC, Abdel-Wahab, Yasser, Barnett, CR and Flatt, Peter (1994) CHARACTERIZATION OF THE GLYCATION OF HUMAN INSULIN BY REVERSED-PHASE HPLC. BIOCHEMICAL SOCIETY TRANSACTIONS, 22 (2). pp. S239.

Abdel-Wahab, Yasser, O'Harte, Finbarr, Barnett, CR and Flatt, Peter (1994) STUDIES OF THE EFFECT OF GLYCATION OF INSULIN ON GLUCOSE-METABOLISM IN ISOLATED MOUSE DIAPHRAGM MUSCLE. BIOCHEMICAL SOCIETY TRANSACTIONS, 22 (2). pp. S238.

This list was generated on Thu Apr 24 06:24:18 2014 BST.